Trader J's Inner Circle Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle

NVDA 175.02

-3.3%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Spark who wrote (2851)	12/30/1998 11:43:00 PM
From: Merg	of 56535

Spark and Hoffy, ASCT NDA The product is simply a new delivery method (system for Acetaminophen (which is Tylenol!) The efficacy of Tylenol has been well established for years but each time a Drug company reformulates the dosage or method of administration a New Drug Application is required. hey just attach the old efficacy data to the NDA submission. This non-approval is for the packaging of the product, the method of delivery but NOT applicable to whether the drug works because that is already known. The advantage to ASCT in creating a unique method of delivery is that this enables them to trademark a product, i.e. 'Feverall', that is no longer protected by a patent. This is not a major setback by any means. JMHO Merg.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next